145 related articles for article (PubMed ID: 22521331)
1. Spatial confinement can lead to increased stability of amorphous indomethacin.
Nielsen LH; Keller SS; Gordon KC; Boisen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2012 Jun; 81(2):418-25. PubMed ID: 22521331
[TBL] [Abstract][Full Text] [Related]
2. Investigations on the effect of different cooling rates on the stability of amorphous indomethacin.
Karmwar P; Boetker JP; Graeser KA; Strachan CJ; Rantanen J; Rades T
Eur J Pharm Sci; 2011 Oct; 44(3):341-50. PubMed ID: 21884789
[TBL] [Abstract][Full Text] [Related]
3. Investigation of properties and recrystallisation behaviour of amorphous indomethacin samples prepared by different methods.
Karmwar P; Graeser K; Gordon KC; Strachan CJ; Rades T
Int J Pharm; 2011 Sep; 417(1-2):94-100. PubMed ID: 21182910
[TBL] [Abstract][Full Text] [Related]
4. A slow cooling rate of indomethacin melt spatially confined in microcontainers increases the physical stability of the amorphous drug without influencing its biorelevant dissolution behaviour.
Nielsen LH; Keller SS; Boisen A; Müllertz A; Rades T
Drug Deliv Transl Res; 2014 Jun; 4(3):268-74. PubMed ID: 25786881
[TBL] [Abstract][Full Text] [Related]
5. The impact of surface- and nano-crystallisation on the detected amorphous content and the dissolution behaviour of amorphous indomethacin.
Priemel PA; Grohganz H; Gordon KC; Rades T; Strachan CJ
Eur J Pharm Biopharm; 2012 Sep; 82(1):187-93. PubMed ID: 22683936
[TBL] [Abstract][Full Text] [Related]
6. Crystallization of amorphous indomethacin during dissolution: effect of processing and annealing.
Greco K; Bogner R
Mol Pharm; 2010 Oct; 7(5):1406-18. PubMed ID: 20459092
[TBL] [Abstract][Full Text] [Related]
7. Monitoring crystallisation of drugs from fast-dissolving oral films with isothermal calorimetry.
Gaisford S; Verma A; Saunders M; Royall PG
Int J Pharm; 2009 Oct; 380(1-2):105-11. PubMed ID: 19596058
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of surface crystallisation of amorphous indomethacin particles in physical drug-polymer mixtures.
Priemel PA; Laitinen R; Barthold S; Grohganz H; Lehto VP; Rades T; Strachan CJ
Int J Pharm; 2013 Nov; 456(2):301-6. PubMed ID: 24012867
[TBL] [Abstract][Full Text] [Related]
9. [Microcosmic mechanisms of amorphous indomethacin crystallization and the influence of nano-coating on crystallization].
Hui OY; Yi T; Zheng Q; Liu F
Yao Xue Xue Bao; 2011 Jun; 46(6):707-12. PubMed ID: 21882533
[TBL] [Abstract][Full Text] [Related]
10. Screening for differences in the amorphous state of indomethacin using multivariate visualization.
Savolainen M; Heinz A; Strachan C; Gordon KC; Yliruusi J; Rades T; Sandler N
Eur J Pharm Sci; 2007 Feb; 30(2):113-23. PubMed ID: 17169536
[TBL] [Abstract][Full Text] [Related]
11. Quantifying crystallisation rates of amorphous pharmaceuticals with dynamic mechanical analysis (DMA).
Soutari N; Buanz AB; Gul MO; Tuleu C; Gaisford S
Int J Pharm; 2012 Feb; 423(2):335-40. PubMed ID: 22101291
[TBL] [Abstract][Full Text] [Related]
12. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation.
Chieng N; Aaltonen J; Saville D; Rades T
Eur J Pharm Biopharm; 2009 Jan; 71(1):47-54. PubMed ID: 18644443
[TBL] [Abstract][Full Text] [Related]
13. Effect of compression on non-isothermal crystallization behaviour of amorphous indomethacin.
Ayenew Z; Paudel A; Rombaut P; Van den Mooter G
Pharm Res; 2012 Sep; 29(9):2489-98. PubMed ID: 22638868
[TBL] [Abstract][Full Text] [Related]
14. Effect of different preparation methods on the dissolution behaviour of amorphous indomethacin.
Karmwar P; Graeser K; Gordon KC; Strachan CJ; Rades T
Eur J Pharm Biopharm; 2012 Feb; 80(2):459-64. PubMed ID: 22019529
[TBL] [Abstract][Full Text] [Related]
15. Using the low-frequency Raman spectroscopy to analyze the crystallization of amorphous indomethacin.
Hédoux A; Paccou L; Guinet Y; Willart JF; Descamps M
Eur J Pharm Sci; 2009 Sep; 38(2):156-64. PubMed ID: 19591926
[TBL] [Abstract][Full Text] [Related]
16. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
Fini A; Cavallari C; Ospitali F
Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516
[TBL] [Abstract][Full Text] [Related]
17. Polymer incorporation method affects the physical stability of amorphous indomethacin in aqueous suspension.
Surwase SA; Itkonen L; Aaltonen J; Saville D; Rades T; Peltonen L; Strachan CJ
Eur J Pharm Biopharm; 2015 Oct; 96():32-43. PubMed ID: 26092472
[TBL] [Abstract][Full Text] [Related]
18. Stability test for amorphous materials in humidity controlled 96-well plates by near-infrared spectroscopy.
Otsuka M; Tanabe H
Drug Dev Ind Pharm; 2012 Mar; 38(3):380-5. PubMed ID: 21942281
[TBL] [Abstract][Full Text] [Related]
19. Stability of indomethacin with relevance to the release from amorphous solid dispersions studied with ATR-FTIR spectroscopic imaging.
Ewing AV; Clarke GS; Kazarian SG
Eur J Pharm Sci; 2014 Aug; 60():64-71. PubMed ID: 24832964
[TBL] [Abstract][Full Text] [Related]
20. Enhanced kinetic solubility profiles of indomethacin amorphous solid dispersions in poly(2-hydroxyethyl methacrylate) hydrogels.
Sun DD; Ju TC; Lee PI
Eur J Pharm Biopharm; 2012 May; 81(1):149-58. PubMed ID: 22233548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
